Helping Daytona Beach patients explore new treatments for atrial fibrillation and stroke prevention through safe, expertly managed clinical studies.
AFib & Stroke Prevention Study
This research study is looking at whether abelacimab, when compared with a placebo, can help prevent ischemic stroke or systemic embolism in people with AF who are considered unsuitable for standard oral blood thinners.
This is a Phase 3, randomized, double-blind, placebo-controlled study — meaning participants are randomly assigned to receive either abelacimab or a placebo, and neither you nor the study team will know which one you’re getting during the study.
Everyone in the study continues to receive their regular medical care.
The study plans to enroll about 1,900 participants and is expected to continue through late 2026.
Why join? By joining this study, you may help researchers learn whether an investigational treatment can reduce the risk of stroke and other clot-related complications in people with atrial fibrillation who cannot take standard blood thinners. Participants receive study-related medical care at no cost from our experienced clinical team and may be compensated for time and travel.
Study Eligibility
Age
Adults 65+
Gender
All genders welcome
Condition
Diagnosed with AFib or Atrial Flutter.
Location
Daytona Beach, FL
Enrolling Now
Fill out the form below to see if you qualify for our afib & stroke prevention study in Daytona Beach. Participation is completely voluntary, and all study-related care will be provided at no cost to you.
Why Join?
Study Sponsor
Reimagining medicine to improve and extend lives
Novartis is a global medicines company developing innovative therapies across cardiovascular, immunology, neuroscience, and oncology. Novartis is the sponsor of the abelacimab and inclisiran clinical programs in development at Arrow.
Participating in a clinical trial at Arrow Clinical Trials in Daytona Beach is an opportunity to take charge of your health while helping advance medical science — all while under the care of experienced local physicians.
From our blog
September is AFib Awareness Month. What atrial fibrillation feels like, why some people feel nothing at all, how to check your own pulse, and when an irregular heartbeat is worth a call.
Read the article →
Atrial fibrillation raises stroke risk significantly — and current treatments do not work for everyone. Learn how a clinical study in Daytona Beach may offer a new option.
Read the article →Daytona Cardiology Clinical Trials
Evaluation of abelacimab versus placebo for the prevention of ischemic stroke and systemic embolism in patients with atrial fibrillation who are unsuitable for standard oral anticoagulant therapy. This study assesses whether targeting Factor XI can reduce clot-related events while minimizing bleeding risk.
We currently conduct research studies in Hypertension, Orthopedics, Cardiology, and Neurology. Our trials include treatments for high blood pressure, joint pain, heart health, stroke recovery, migraines, and other conditions affecting the brain and nervous system.
No. All studies at Arrow Clinical Trials are provided at no cost to participants, and insurance is not required. Any procedures, tests, or study-related care will be covered by the trial sponsor.
Yes. Participants may receive compensation for their time and travel. The exact amount depends on the study and the number of visits required.
Each study has specific requirements, such as age range, medical history, and current health status. Our research team will review your information and conduct a screening process to determine if you qualify.
Your feedback is invaluable to us. Please take a moment to share your experience with Arrow Clinical Trials.
